ProCE Banner Activity

Individualizing Management in T2D With CKD

Slideset Download

A leading expert provides an overview of the considerations for management of CKD associated with T2D, with a focus on pharmacotherapy options.

Released: September 21, 2022

Expiration: September 20, 2023

Share

Faculty

Vivian A. Fonseca

Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences center
New Orleans, Louisiana

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by independent educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Boehringer Ingelheim and Eli Lilly

Faculty Disclosure

Primary Author

Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences center
New Orleans, Louisiana

Vivian Fonseca, MD, FRCP: researcher (support paid to institution): Fractyl, Jaguar Gene Therapy; consultant/advisor/speaker: Abbott, Asahi, AstraZeneca, Novo Nordisk, Sanofi; stock/stock options: Abbott, Amgen, BRAVO4Health, Mellitus Health; patent: BRAVO Risk Engine for Predicting Diabetes Complications.